Intergroupe Francophone du Myelome
22
2
9
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
18.2%
4 terminated/withdrawn out of 22 trials
66.7%
-19.8% vs industry average
27%
6 trials in Phase 3/4
13%
1 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
Role: collaborator
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients
Role: lead
Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma
Role: lead
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Role: lead
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
Role: collaborator
A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)
Role: collaborator
Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care
Role: collaborator
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
Role: lead
IPD in RRMM Characterized with Genomic Abnormalities of Adverse Prognostic
Role: lead
MInimal Residual Disease Adapted Strategy
Role: lead
Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy
Role: lead
Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.
Role: lead
Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma
Role: lead
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
Role: collaborator
Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.
Role: collaborator
Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone
Role: lead
Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma
Role: collaborator
Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma
Role: lead
Maintenance Therapy Using Lenalidomide in Myeloma
Role: collaborator
Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)
Role: collaborator